Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions reflect a generally positive outlook on the article, mentioning its implications for long-term depression treatment and referencing specific studies like TRANSFORM-1 and SUSTAIN-1. Words such as 'important finding' and 'potentially significant' convey the perceived impact, while references to conflicts of interest suggest critical engagement.
Many discussions support the article's findings, emphasizing the benefits of esketamine in relapse prevention.
Posts show moderate curiosity, with some referencing specific trials and potential conflicts of interest.
Several mentions include detailed study results, such as relapse rates and clinical implications, indicating thoughtful engagement.
Discussions highlight the significance of the research for treatment options, showing recognition of its potential influence in psychiatry.
Los autores del principal trabajo en el que se apoya el spray nasal ese para la depresión reconocen conflicto de intereses. Pero bueno, después de 50 líneas de texto finaliza con un "no other disclosures were reported" así que OK https://t.co/XyFFjBvqE0 https://t.co/tOpXM73vFp https://t.co/ExXGqviIFh
Continued treatment with #esketamine nasal spray plus an #antidepressant can sustain antidepressant effects among patients with treatment resistant #depression to a greater extent than an oral antidepressant alone https://t.co/LCOLBgjbeu
Esketamine Nasal Spray Plus Oral Antidepressant Treatment in Patients With Treatment-Resistant Depression https://t.co/bfSEnmz640 #mostcited
Continued treatment with #esketamine nasal spray plus an #antidepressant can sustain antidepressant effects among patients with treatment resistant #depression to a greater extent than an oral antidepressant alone. https://t.co/QpBruMiyNM
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2019 Jun 5.
تجربة عمياء محكمة على مرضى اكتئاب مقاوم تحسنوا بداية على بخاخ الإيزكيتامين مع دواء آخر و بالمرحلة الثانية قسموهم لقسم يستمر بالبخاخ و قسم ببخاخ وهمي لقياس حماية الإيزكيتامين ضد الانتكاسة بالأمد البعيد النتيجة حماية تصل ل ٧٠٪ مع الإزكيتامين الدراسة كاملة https://t.co/i5lJsVE6dB
Esketamine is not just a simple journey; it is a clinical tool with solid evidence in treating resistant depression. It provides persistent improvement and lowers relapse risk compared to oral antidepressants. This…
Intranasal Esketamine shows utility in two clinical scenarios: treatment-resistant depression and acute suicidal ideation. Patients who have not responded to multiple treatment strategies may benefit from Spravato…
Typical ketamine treatment: ketamine dose kept constant but frequency of treatments decreases Esketamine protects against relapse in treatment resistant depression (TRD) responders (OR=0.3) https://t.co/xtNMt0iLud
@ee_schenberg @joarhalvorsen @AAMortazavi @CarleneMac @Drug_Researcher Have to agree w @joarhalvorsen … compass is doing long term f/u and Janssen did too https://t.co/h1pNMd8jZK https://t.co/c96hijl0SW All I’m saying is it’s do-able. Approvable even. Design will have to be a bit different for mdma, but not an unreasonable ask for 1st in class
RT @EdgarArtacho: Los autores del principal trabajo en el que se apoya el spray nasal ese para la depresión reconocen conflicto de interese…
RT @EdgarArtacho: Los autores del principal trabajo en el que se apoya el spray nasal ese para la depresión reconocen conflicto de interese…
RT @EdgarArtacho: Los autores del principal trabajo en el que se apoya el spray nasal ese para la depresión reconocen conflicto de interese…
RT @EdgarArtacho: Los autores del principal trabajo en el que se apoya el spray nasal ese para la depresión reconocen conflicto de interese…
RT @EdgarArtacho: Los autores del principal trabajo en el que se apoya el spray nasal ese para la depresión reconocen conflicto de interese…
RT @EdgarArtacho: Los autores del principal trabajo en el que se apoya el spray nasal ese para la depresión reconocen conflicto de interese…
RT @EdgarArtacho: Los autores del principal trabajo en el que se apoya el spray nasal ese para la depresión reconocen conflicto de interese…
RT @EdgarArtacho: Los autores del principal trabajo en el que se apoya el spray nasal ese para la depresión reconocen conflicto de interese…
RT @EdgarArtacho: Los autores del principal trabajo en el que se apoya el spray nasal ese para la depresión reconocen conflicto de interese…
Los autores del principal trabajo en el que se apoya el spray nasal ese para la depresión reconocen conflicto de intereses. Pero bueno, después de 50 líneas de texto finaliza con un "no other disclosures were reported" así que OK https://t.co/XyFFjBvqE0 https://t.co/tOpXM73vFp https://t.co/ExXGqviIFh
@Mikeofthegalaxy @kevint02923060 @sabotagebeats @TheCryptoDog That’s not the only study.
RT @JAMAPsych: Esketamine Nasal Spray Plus Oral Antidepressant Treatment in Patients With Treatment-Resistant Depression https://t.co/bfSEn…
RT @JAMAPsych: Esketamine Nasal Spray Plus Oral Antidepressant Treatment in Patients With Treatment-Resistant Depression https://t.co/bfSEn…
RT @JAMAPsych: Esketamine Nasal Spray Plus Oral Antidepressant Treatment in Patients With Treatment-Resistant Depression https://t.co/bfSEn…
Esketamine Nasal Spray Plus Oral Antidepressant Treatment in Patients With Treatment-Resistant Depression https://t.co/bfSEnmz640 #mostcited
RT @JAMAPsych: Esketamine Nasal Spray Plus Oral Antidepressant Treatment in Patients With Treatment-Resistant Depression https://t.co/bfSEn…
RT @JAMAPsych: Esketamine Nasal Spray Plus Oral Antidepressant Treatment in Patients With Treatment-Resistant Depression https://t.co/bfSEn…
RT @JAMAPsych: Esketamine Nasal Spray Plus Oral Antidepressant Treatment in Patients With Treatment-Resistant Depression https://t.co/bfSEn…
RT @JAMAPsych: Esketamine Nasal Spray Plus Oral Antidepressant Treatment in Patients With Treatment-Resistant Depression https://t.co/bfSEn…
RT @JAMAPsych: Esketamine Nasal Spray Plus Oral Antidepressant Treatment in Patients With Treatment-Resistant Depression https://t.co/bfSEn…
RT @JAMAPsych: Esketamine Nasal Spray Plus Oral Antidepressant Treatment in Patients With Treatment-Resistant Depression https://t.co/bfSEn…
Esketamine Nasal Spray Plus Oral Antidepressant Treatment in Patients With Treatment-Resistant Depression https://t.co/m9iPM14b2b https://t.co/8wzKnIsPoK
Esketamine Nasal Spray Plus Oral Antidepressant Treatment in Patients With Treatment-Resistant Depression https://t.co/bfSEnmz640 #mostcited
@mmc_im Several recent trials, including TRANSFORM-1, showed the superiority of ketamine + oral antidepressants vs. antidepressants in delaying relapse in TRD. https://t.co/Q0cEPQ3z7C https://t.co/odYbZdpiQF
Journal Club - Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial https://t.co/6RcgFMWCN3 https://t.co/H1HBK7Mpau
RT @JAMAPsych: https://t.co/786BBjfvs6
RT @JAMAPsych: https://t.co/786BBjfvs6
RT @JAMAPsych: https://t.co/786BBjfvs6
https://t.co/786BBjfvs6
#JournalClub! Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial
RT @JAMAPsych: https://t.co/726F0t63Aw
RT @JAMAPsych: https://t.co/726F0t63Aw
https://t.co/726F0t63Aw
Journal Club - Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial https://t.co/UcsyvQrgXV https://t.co/hcrKzyD1rJ
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With... https://t.co/q1EChRcawp
RT @JAMAPsych: https://t.co/QBEnQGzyxN
RT @JAMAPsych: https://t.co/QBEnQGzyxN
RT @JAMAPsych: https://t.co/QBEnQGzyxN
https://t.co/QBEnQGzyxN
RT @psychopharmacol: For patients with TRD who experienced remission or response after esketamine treatment, continuation of esketamine nas…
For patients with TRD who experienced remission or response after esketamine treatment, continuation of esketamine nasal spray + oral antidepressant resulted in clinically superiority in delaying relapse vs. antidepressant + placebo (HR=0.49; 0.29-0.84) https://t.co/wbB5fpS9DR
RT @JAMAPsych: Continued treatment with #esketamine nasal spray plus an #antidepressant can sustain antidepressant effects among patients w…
Esketamine Nasal Spray Plus Oral Antidepressant Treatment in Patients With Treatment-Resistant Depression https://t.co/kz3SjBkAcf
RT @JAMAPsych: Continued treatment with #esketamine nasal spray plus an #antidepressant can sustain antidepressant effects among patients w…
RT @JAMAPsych: Continued treatment with #esketamine nasal spray plus an #antidepressant can sustain antidepressant effects among patients w…
RT @JAMAPsych: Continued treatment with #esketamine nasal spray plus an #antidepressant can sustain antidepressant effects among patients w…
RT @JAMAPsych: Continued treatment with #esketamine nasal spray plus an #antidepressant can sustain antidepressant effects among patients w…
RT @JAMAPsych: Continued treatment with #esketamine nasal spray plus an #antidepressant can sustain antidepressant effects among patients w…
Continued treatment with #esketamine nasal spray plus an #antidepressant can sustain antidepressant effects among patients with treatment resistant #depression to a greater extent than an oral antidepressant alone https://t.co/LCOLBgjbeu
RT @JAMAPsych: https://t.co/bTu87VoKhp
RT @JAMAPsych: https://t.co/bTu87VoKhp
https://t.co/bTu87VoKhp
"Continued treatment with Esketamine nasal spray plus an antidepressant can sustain antidepressant effects among patients with treatment-resistant depression to a greater extent than an oral antidepressant alone." ~ https://t.co/QBVBexr8gA https://t.co/IvR7guICh7
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial https://t.co/vP9hNVeHGD
RT @JRB_Neuropsiq: Esketamine Nasal Spray Plus Oral Antidepressant Treatment in Patients With Treatment-Resistant Depression https://t.co/W…
Esketamine Nasal Spray Plus Oral Antidepressant Treatment in Patients With Treatment-Resistant Depression https://t.co/WxfOLV8612
New2Trip: Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients w/ Treatment-Resistant Depression: Randomized Clinical Trial https://t.co/9TM5TZczZp
New2Trip: Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients w/ Treatment-Resistant Depression: Randomized Clinical Trial https://t.co/9TM5TZczZp
New2Trip: Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients w/ Treatment-Resistant Depression: Randomized Clinical Trial https://t.co/KoYZYKcYld
New2Trip: Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients w/ Treatment-Resistant Depression: Randomized Clinical Trial https://t.co/9TM5TZczZp
New2Trip: Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients w/ Treatment-Resistant Depression: Randomized Clinical Trial https://t.co/KoYZYKcYld
New2Trip: Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients w/ Treatment-Resistant Depression: Randomized Clinical Trial https://t.co/9TM5TZczZp
New2Trip: Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients w/ Treatment-Resistant Depression: Randomized Clinical Trial https://t.co/9TM5TZczZp
New2Trip: Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients w/ Treatment-Resistant Depression: Randomized Clinical Trial https://t.co/KoYZYKcYld
New2Trip: Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients w/ Treatment-Resistant Depression: Randomized Clinical Trial https://t.co/9TM5TZczZp
RT @sakura_tnh: Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Res…
RT @sakura_tnh: Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Res…
RT @sakura_tnh: Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Res…
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2019 Jun 5.
EvidenceAlerts | Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. https://t.co/10aO7cUH2v
Esketamine Nasal Spray Plus Oral Antidepressant Treatment in Patients With Treatment-Resistant Depression https://t.co/bSmLlOka9i
RT @Psychiatry_DDx: تجربة عمياء محكمة على مرضى اكتئاب مقاوم تحسنوا بداية على بخاخ الإيزكيتامين مع دواء آخر و بالمرحلة الثانية قسموهم لقسم ي…
RT @Psychiatry_DDx: تجربة عمياء محكمة على مرضى اكتئاب مقاوم تحسنوا بداية على بخاخ الإيزكيتامين مع دواء آخر و بالمرحلة الثانية قسموهم لقسم ي…
RT @Psychiatry_DDx: تجربة عمياء محكمة على مرضى اكتئاب مقاوم تحسنوا بداية على بخاخ الإيزكيتامين مع دواء آخر و بالمرحلة الثانية قسموهم لقسم ي…
RT @Psychiatry_DDx: تجربة عمياء محكمة على مرضى اكتئاب مقاوم تحسنوا بداية على بخاخ الإيزكيتامين مع دواء آخر و بالمرحلة الثانية قسموهم لقسم ي…
تجربة عمياء محكمة على مرضى اكتئاب مقاوم تحسنوا بداية على بخاخ الإيزكيتامين مع دواء آخر و بالمرحلة الثانية قسموهم لقسم يستمر بالبخاخ و قسم ببخاخ وهمي لقياس حماية الإيزكيتامين ضد الانتكاسة بالأمد البعيد النتيجة حماية تصل ل ٧٠٪ مع الإزكيتامين الدراسة كاملة https://t.co/i5lJsVE6dB
RT @dawso007: Useful study on dosing protocol but how do you find that many mod - severe depressions with no SI? I guess you have to look f…
Useful study on dosing protocol but how do you find that many mod - severe depressions with no SI? I guess you have to look for them. Esketamine Nasal Spray Plus Oral Antidepressant Treatment in Patients With Treatment-Resistant Depression https://t.co/CoQudzbgvM
https://t.co/QBEnQGzyxN
Guess which is the only of these trials to get published? That's right, the maintenance RCT (nicely branded as "long term effects"). This is study 3003 (SUSTAIN-1) in the @US_FDA PDAC. Spot all the differences https://t.co/iuvsv6DxZc
RT @PeterDKramer: Potentially important finding: In maintenance phase, adding esketamine to antidepressant cut relapse rate sharply. But be…
In patients with treatment-resistant #depression who responded to intranasal #esketamine plus an #antidepressant, maintaining that treatment regimen significantly reduced their risk of relapse, according to a study in @JAMAPsych | #psychiatry https://t.co/q60ZHqNUPN
Potentially important finding: In maintenance phase, adding esketamine to antidepressant cut relapse rate sharply. But best result required weekly visit to pharmacologist, & giving ESK w AD erases one of ESK's advantages, reduced time of exposure to meds. https://t.co/08Bwq4TMW6
Lower relapse rate but I’d like to see it without the conflicts of interest: Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: RCT| JAMA Psychiatry https://t.co/Y6XUXvYmgV
RT @JAMAPsych: Continued treatment with #esketamine nasal spray plus an #antidepressant can sustain antidepressant effects among patients w…
RT @JAMAPsych: Continued treatment with #esketamine nasal spray plus an #antidepressant can sustain antidepressant effects among patients w…
RT @JAMAPsych: Continued treatment with #esketamine nasal spray plus an #antidepressant can sustain antidepressant effects among patients w…
RT @JAMAPsych: Continued treatment with #esketamine nasal spray plus an #antidepressant can sustain antidepressant effects among patients w…
RT @JAMAPsych: Continued treatment with #esketamine nasal spray plus an #antidepressant can sustain antidepressant effects among patients w…
RT @JAMAPsych: Continued treatment with #esketamine nasal spray plus an #antidepressant can sustain antidepressant effects among patients w…
Continued treatment with #esketamine nasal spray plus an #antidepressant can sustain antidepressant effects among patients with treatment resistant #depression to a greater extent than an oral antidepressant alone. https://t.co/QpBruMiyNM
EM
JP
さ
لد
TE
BH
K
L
CS
TM
PD
AP
PC
CG
RN
M
Յ
BB
DJ
ML
F
KM
GR
اا
J
JR
OM
OF
A
ÁM
AL
IL
CG
HP
M
DG
K
CM
AS
P
JK
J
PR
JR
GA
SB
JK
MW
N
N
PS
YC
JB
TC
TD
P
琉肉
ま
JM
FS
ال
O
KA
أ
B
GD
IC
SP
SD
P
LF
J
BM
AP
PM
SC